ADC Therapeutics Announces Preclinical Data Highlighted at the American Association for Cancer Research Annual Meeting 2025
ADC Therapeutics (NYSE: ADCT) presented preclinical data for three exatecan-based antibody drug conjugates (ADCs) at the AACR Annual Meeting 2025. The key highlight was ADCT-242, targeting Claudin-6, which demonstrated potent antitumor activity in ovarian and non-small lung cancer models, with good tolerance up to 150 mg/kg in mice and 40 mg/kg in cynomolgus monkeys.
Additionally, ADCT-241, targeting PSMA, showed promising results in prostate cancer models with synergistic effects when combined with enzalutamide. The third ADC, HuB14-VA-PL2202, targeting ASCT2, exhibited potent antitumor activity in both solid and hematological cancer cell lines with good tolerability in preclinical studies.
ADC Therapeutics (NYSE: ADCT) ha presentato dati preclinici su tre coniugati anticorpo-farmaco (ADC) a base di exatecan durante l'AACR Annual Meeting 2025. Il punto focale è stato ADCT-242, che prende di mira Claudin-6, dimostrando una potente attività antitumorale in modelli di tumore ovarico e di carcinoma polmonare non a piccole cellule, con buona tolleranza fino a 150 mg/kg nei topi e 40 mg/kg nei macachi cynomolgus.
Inoltre, ADCT-241, diretto contro PSMA, ha mostrato risultati promettenti in modelli di cancro alla prostata con effetti sinergici se combinato con enzalutamide. Il terzo ADC, HuB14-VA-PL2202, mirato ad ASCT2, ha evidenziato una forte attività antitumorale sia in linee cellulari di tumori solidi che ematologici, con buona tollerabilità negli studi preclinici.
ADC Therapeutics (NYSE: ADCT) presentó datos preclínicos de tres conjugados anticuerpo-fármaco (ADC) basados en exatecan en la Reunión Anual AACR 2025. El punto destacado fue ADCT-242, dirigido contra Claudin-6, que demostró una potente actividad antitumoral en modelos de cáncer de ovario y de pulmón no microcítico, con buena tolerancia hasta 150 mg/kg en ratones y 40 mg/kg en monos cynomolgus.
Además, ADCT-241, dirigido a PSMA, mostró resultados prometedores en modelos de cáncer de próstata con efectos sinérgicos al combinarse con enzalutamida. El tercer ADC, HuB14-VA-PL2202, dirigido a ASCT2, exhibió potente actividad antitumoral tanto en líneas celulares de cáncer sólido como hematológico, con buena tolerabilidad en estudios preclínicos.
ADC Therapeutics (NYSE: ADCT)는 2025년 AACR 연례회의에서 엑사테칸 기반 항체-약물 접합체(ADC) 3종의 전임상 데이터를 발표했습니다. 주요 내용은 Claudin-6를 표적으로 하는 ADCT-242로, 난소암 및 비소세포폐암 모델에서 강력한 항종양 활성을 보였으며, 쥐에서는 150 mg/kg, 사이놈롤거스 원숭이에서는 40 mg/kg까지 양호한 내약성을 나타냈습니다.
또한, PSMA를 표적으로 하는 ADCT-241은 전립선암 모델에서 유망한 결과를 보였으며, 엔잘루타마이드와 병용 시 상승 효과가 확인되었습니다. 세 번째 ADC인 HuB14-VA-PL2202는 ASCT2를 표적으로 하여 고형암 및 혈액암 세포주 모두에서 강력한 항종양 활성을 보였고, 전임상 연구에서 좋은 내약성을 보였습니다.
ADC Therapeutics (NYSE : ADCT) a présenté des données précliniques sur trois conjugués anticorps-médicament (ADC) à base d'exatecan lors de la réunion annuelle AACR 2025. Le point fort était ADCT-242, ciblant Claudin-6, qui a démontré une puissante activité antitumorale dans des modèles de cancer de l'ovaire et du poumon non à petites cellules, avec une bonne tolérance jusqu'à 150 mg/kg chez la souris et 40 mg/kg chez le singe cynomolgus.
De plus, ADCT-241, ciblant le PSMA, a montré des résultats prometteurs dans des modèles de cancer de la prostate avec des effets synergiques en combinaison avec l'enzalutamide. Le troisième ADC, HuB14-VA-PL2202, ciblant ASCT2, a présenté une forte activité antitumorale à la fois dans des lignées cellulaires de cancers solides et hématologiques, avec une bonne tolérance dans les études précliniques.
ADC Therapeutics (NYSE: ADCT) stellte auf der AACR-Jahrestagung 2025 präklinische Daten zu drei exatecan-basierten Antikörper-Wirkstoff-Konjugaten (ADCs) vor. Das Highlight war ADCT-242, das Claudin-6 anvisiert und in Modellen von Eierstock- und nicht-kleinzelligem Lungenkrebs eine starke antitumorale Wirkung zeigte, mit guter Verträglichkeit bis zu 150 mg/kg bei Mäusen und 40 mg/kg bei Pavianen.
Zusätzlich zeigte ADCT-241, das auf PSMA abzielt, vielversprechende Ergebnisse in Prostatakrebsmodellen mit synergistischen Effekten in Kombination mit Enzalutamid. Das dritte ADC, HuB14-VA-PL2202, das ASCT2 anvisiert, zeigte starke antitumorale Aktivität sowohl in soliden als auch hämatologischen Krebszelllinien mit guter Verträglichkeit in präklinischen Studien.
- Successful preclinical results for three different ADC candidates
- ADCT-242 showed strong antitumor activity with good therapeutic index
- ADCT-241 demonstrated synergy with existing prostate cancer treatment enzalutamide
- HuB14-VA-PL2202 showed effectiveness across both solid and hematological cancers
- All studies are still in preclinical phase, requiring significant development before potential commercialization
- No human trial data available yet to confirm safety and efficacy
Oral presentation shows ADCT-242 targeting Claudin-6 was well-tolerated and demonstrated potent
antitumor activity in ovarian and non-small lung cancer
Poster presentations highlight antitumor activity and safety of novel PSMA-targeted and ASCT2-
targeted ADCs
LAUSANNE,
"We believe these presentations demonstrate the strong potential of our exatecan-based ADCs to treat a wide range of solid and hematologic cancers beyond lymphoma. The data from the oral presentation of our CLDN6-targeted ADC show its potential, both as a single agent and in combination, to treat ovarian and non-small cell lung cancers," said Patrick van Berkel, PhD, Chief Scientific Officer of ADC Therapeutics. "Our additional presentations showcase compelling data validating the potency and tolerability of our PSMA-targeting and ASCT2-targeting ADCs."
Data from the preclinical investigation of ADCT-242, a novel exatecan-based ADC targeting CLDN6, were presented in an oral presentation titled, "Preclinical investigation of ADCT-242, a novel exatecan-based antibody drug conjugate targeting Claudin-6, as single agent or in combination in ovarian and non-small lung cancer models." Key highlights from this presentation include:
- ADCT-242 demonstrated potent anti-tumor activity in vivo in PA-1 and OVCAR-3 xenograft models with medium CLDN6 expression
- CLDN6-dependent anti-tumor activity of ADCT-242 was observed in lung patient-derived tumor models
- ADCT-242 was tolerated in mice or cynomolgus monkeys at doses up to 150 mg/kg or 40 mg/kg, respectively, indicative of a good therapeutic index
Data from the preclinical investigation of ADCT-241, a novel PSMA-targeting ADC, were presented in a poster presentation titled, "Preclinical Development of ADCT-241, a Novel Exatecan-based Antibody-Drug Conjugate Targeting PSMA for the Treatment of Prostate Cancer." The data demonstrated antitumor activity in both xenograft and patient-derived PSMA-expressing prostate cancer models as well as synergy with enzalutamide. ADCT-241 was well tolerated in both rats and cynomolgus monkeys.
Data from the preclinical investigation of HuB14-VA-PL2202, a novel ASCT2-targeting ADC, were presented in a poster presentation titled, "HuB14-VA-PL2202, a novel antibody-drug conjugate targeting ASCT2, a novel ADC target over-expressed in both solid and hematological cancers." The data demonstrated potent and specific in vitro and in vivo antitumor activity of HuB14-VA-PL2202 in ASCT2-positive solid and hematological cancer cell lines, and HuB14-VA-PL2202 was well-tolerated in cynomolgus monkeys.
To access the full AACR Annual Meeting 2025 program, visit the AACR Annual Meeting website.
About ADC Therapeutics
ADC Therapeutics (NYSE: ADCT) is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs). The Company is advancing its proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies and solid tumors.
ADC Therapeutics' CD19-directed ADC ZYNLONTA (loncastuximab tesirine-lpyl) received accelerated approval by the FDA and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma after two or more lines of systemic therapy. ZYNLONTA is also in development in combination with other agents and in earlier lines of therapy. In addition to ZYNLONTA, ADC Therapeutics has multiple ADCs in ongoing clinical and preclinical development.
ADC Therapeutics is based in Lausanne (Biopôle),
ZYNLONTA® is a registered trademark of ADC Therapeutics SA.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. In some cases you can identify forward-looking statements by terminology such as "may", "will", "should", "would", "expect", "intend", "plan", "anticipate", "believe", "estimate", "predict", "potential", "seem", "seek", "future", "continue", or "appear" or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: the timing and future results of the Company's early research in exatecan-based Claudin-6, PSMA and ASCT2-targeting antibody-drug conjugates; the expected cash runway into mid-2026 the Company's ability to grow ZYNLONTA® revenue in
CONTACTS:
Investors
Marcy Graham
ADC Therapeutics
Marcy.Graham@adctherapeutics.com
+1 650-667-6450
Media
Nicole Riley
ADC Therapeutics
Nicole.Riley@adctherapeutics.com
+1 862-926-9040
View original content to download multimedia:https://www.prnewswire.com/news-releases/adc-therapeutics-announces-preclinical-data-highlighted-at-the-american-association-for-cancer-research-annual-meeting-2025-302438880.html
SOURCE ADC Therapeutics SA
FAQ
What were the key findings for ADCT-242 in ovarian and lung cancer trials?
How well was ADCT-242 tolerated in preclinical studies?
What were the results of ADCT-241 in prostate cancer treatment?
What potential does HuB14-VA-PL2202 show for cancer treatment?
